35.56
+0.03(+0.08%)
Currency In USD
Address
2101 Cottontail Lane
Somerset, NJ 08873
United States of America
Phone
732 317 5050
Sector
Healthcare
Industry
Biotechnology
Employees
2600
First IPO Date
June 05, 2020
| Name | Title | Pay | Year Born |
| Dr. Ying Huang Ph.D. | Chief Executive Officer & Director | 0 | 1973 |
| Mr. Tim Roberts | Global Compliance Officer | 0 | N/A |
| Mr. Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply | 0 | N/A |
| Ms. Elaine Qian | Vice President & Global Head of Human Resources | 0 | N/A |
| Ms. Caroline LeCates Paul | Associate Director of Investor Relations | 0 | N/A |
| Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer | 0 | 1979 |
| Mr. Shu Wu | Senior Vice President of Global Operations & GM of Legend China | 0 | N/A |
| Ms. Jessie Yeung M.B.A. | Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 0 | 1985 |
| Dr. Guowei Fang Ph.D. | President of Research & Development | 0 | N/A |
| Mr. James Pepin J.D. | General Counsel | 0 | N/A |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.